公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2022 | Organization capital effect in stock returns—The role of R&D | Chan K; Li M.-X; Lin C.-B; YAN-ZHI WANG | Journal of Business Finance and Accounting | |||
2017 | Phase III, randomized, placebo-controlled, double-blind trial of motesanib (AMG-706) in combination with paclitaxel and carboplatin in east asian patients with advanced nonsquamous non-small-cell lung cancer | Kubota K; Asato T; Hara K; Yoshioka H; Oshita F; Hida T; Yoh K; Nakagawa K; Hayashi H; Kaneda H; Kato T; Yamada K; Ichinose Y; Tanaka H; Park K; Cho E.K; Lee K.-H; Lin C.-B; CHIH-HSIN YANG | Journal of Clinical Oncology | 32 | 28 |